Agenus (NASDAQ: AGEN) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Agenus to related businesses based on the strength of its analyst recommendations, earnings, valuation, profitability, institutional ownership, risk and dividends.
Volatility and Risk
Agenus has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Agenus’ competitors have a beta of 1.48, suggesting that their average stock price is 48% more volatile than the S&P 500.
Earnings and Valuation
This table compares Agenus and its competitors top-line revenue, earnings per share and valuation.
Agenus’ competitors have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a summary of recent recommendations for Agenus and its competitors, as reported by MarketBeat.
||Strong Buy Ratings
Agenus currently has a consensus target price of $6.33, indicating a potential upside of 63.23%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.13%. Given Agenus’ stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than its competitors.
Insider & Institutional Ownership
37.9% of Agenus shares are held by institutional investors. Comparatively, 49.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.9% of Agenus shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Agenus and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Agenus competitors beat Agenus on 7 of the 13 factors compared.
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.